CA-TALKDESK
25.3.2024 16:26:28 CET | Business Wire | Press release
Talkdesk, Inc., a global AI-powered contact center leader for enterprises of all sizes, is enabling contact centers to elevate their customer experiences, empower agents, and streamline operations using Talkdesk Ascend Connect, the industry’s first generative artificial intelligence (GenAI) suite for on-premises environments. Announced today at Enterprise Connect 2024, Talkdesk Ascend Connect allows enterprises to harness the power of large language models (LLMs) and GenAI without overhauling their existing technology stack.
According to the 2023 Gartner® Forecast Analysis: Contact Center, Worldwide*, “the global conversational AI and virtual assistant market represents the fastest-growing segment in the contact center forecast with a projected 57.6% compound annual growth rate (CAGR) from 2022 through 2027.” However, until now, most contact centers using legacy on-premises contact centers have been unable to access the power of GenAI because of the difficulty integrating this game-changing technology with their existing infrastructure.
Talkdesk Ascend Connect solves this challenge. Its flexible GenAI suite comprises four powerful components: Talkdesk Autopilot for conversational AI that can resolve complex queries autonomously, Talkdesk Copilot with a real-time virtual assistant for agents, Talkdesk Interaction Analytics to provide rich operational insights, and Talkdesk AI Trainer™ for responsible GenAI.
Talkdesk Ascend Connect can be used in any enterprise contact center using legacy third-party on-premises contact center solutions.
What makes Talkdesk Ascend Connect unique is its no-code intuitive interface backed by Talkdesk AI Trainer and pre-built AI components. This allows information technology (IT) teams and developers to rapidly deploy, customize, and maintain GenAI models through simple drag-and-drop tools. This accelerates time-to-value without needing in-house data scientists or specialists with AI or machine learning (ML) expertise.
Since 2018, Talkdesk has been a pioneer in combining AI with cloud contact center solutions. This first-mover advantage allowed the company to develop robust, enterprise-grade AI models and a proven platform recognized for its security, compliance, and reliability. Talkdesk solutions meet the highest security standards, with more than 30 certifications, including SOC, 27001, PCI DSS Level 1, HIPAA, and GDPR compliance. Talkdesk is also designated FedRAMP In Process, indicating it will meet the necessary security standards set by the U.S. government.
More information about Talkdesk Ascend Connect and the full Talkdesk GenAI portfolio can be found on the Talkdesk website or at Enterprise Connect 2024 in Talkdesk Booth 1729.
Supporting Quote
Tiago Paiva, chief executive officer and founder at Talkdesk, said: “Generative AI is revolutionizing customer experience by enabling personalized, data-driven interactions while dramatically enhancing contact center productivity. For many contact centers, however, adopting this game-changing technology has been difficult due to the complexities of integrating AI with on-premises infrastructure. Talkdesk Ascend Connect solves that challenge. Whether you want to fuel business expansion, elevate customer experiences, empower agents, or streamline operations, Talkdesk Ascend Connect’s flexible AI suite allows these enterprises to transform their CX strategy for the GenAI era.”
*Gartner, Forecast Analysis: Contact Center, Worldwide; Gartner; May 10, 2023; Megan Fernandez, Daniel O'Connell. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Talkdesk
TalkdeskⓇ is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325539894/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom